The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | A targeted treatment with anti-CD19 CAR T-cells results in different responses
David Maloney, MD, PhD, from Seattle Cancer Care Alliance, USA gives an overview of the anti-CD19 CAR T-cell trial (NCT01865617) at the European Haematological Association (EHA) 2017 in Madrid, Spain. Dr Maloney explains that the trial included all CD 19+ve malignancies including acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). He explains how despite these malignancies being CD19 positive, they all responded to the T cell treatment differently.
